Summary
Global Markets Direct’s, ‘Hairy Cell Leukemia - Pipeline Review, H1 2016’, provides an overview of the Hairy Cell Leukemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia
- The report reviews pipeline therapeutics for Hairy Cell Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hairy Cell Leukemia therapeutics and enlists all their major and minor projects
- The report assesses Hairy Cell Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Biogenomics Limited
F. Hoffmann-La Roche Ltd.
Incyte Corporation
Juno Therapeutics Inc.
MedImmune, LLC
Novartis AG
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia - Overview 8
Hairy Cell Leukemia - Therapeutics under Development by Companies 9
Hairy Cell Leukemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hairy Cell Leukemia - Products under Development by Companies 14
Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15
AbbVie Inc. 15
Astellas Pharma Inc. 16
AstraZeneca Plc 17
Biogenomics Limited 18
F. Hoffmann-La Roche Ltd. 19
Incyte Corporation 20
Juno Therapeutics Inc. 21
MedImmune, LLC 22
Novartis AG 23
Hairy Cell Leukemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(INCB-039110 + INCB-040093) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AGS-67E - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AZD-6738 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ibrutinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
INCB-40093 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
INCB-50465 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
interferon alfa-2a - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
interferon alfa-2b - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
interferon alfa-2b - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
itacitinib adipate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
JCAR-015 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
moxetumomab pasudotox - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
vemurafenib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Hairy Cell Leukemia - Recent Pipeline Updates 64
Hairy Cell Leukemia - Dormant Projects 97
Hairy Cell Leukemia - Discontinued Products 98
Hairy Cell Leukemia - Product Development Milestones 99
Featured News & Press Releases 99
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101
List of Tables
Number of Products under Development for Hairy Cell Leukemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Comparative Analysis by Unknown Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Hairy Cell Leukemia - Pipeline by AbbVie Inc., H1 2016 15
Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H1 2016 16
Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, H1 2016 17
Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H1 2016 18
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 19
Hairy Cell Leukemia - Pipeline by Incyte Corporation, H1 2016 20
Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc., H1 2016 21
Hairy Cell Leukemia - Pipeline by MedImmune, LLC, H1 2016 22
Hairy Cell Leukemia - Pipeline by Novartis AG, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Assessment by Combination Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Hairy Cell Leukemia Therapeutics - Recent Pipeline Updates, H1 2016 64
Hairy Cell Leukemia - Dormant Projects, H1 2016 97
Hairy Cell Leukemia - Discontinued Products, H1 2016 98
List of Figures
Number of Products under Development for Hairy Cell Leukemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 24
Assessment by Combination Products, H1 2016 25
Number of Products by Top 10 Targets, H1 2016 26
Number of Products by Stage and Top 10 Targets, H1 2016 26
Number of Products by Top 10 Mechanism of Actions, H1 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32
